2Merrill JT.Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus.Lupus,2004,13:869-876.
3Miyakis S,Lockshin MD,Atsumi T,et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (AIRS).J Thromb Haemost,2006,4:295-306.
4Cugno M,Cabibbe M,Galli M,et al.Antibodies to tissue-type plasminogen activator (t-PA) in patients with antiphospholipid syndrome:evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients.Blood,2004,103:2121-2126.
5Lu CS,Horizon AA,Hwang KK,et al.Identification of polyclonal and monoclonal antibodies against tissue-type plasminogen activator in the antiphospholipid syndrome.Arthritis Rheum,2005,52:4018-4027.
6Emans N,Gorvel JP,Walter C,et al.Annexin Ⅱ is a major component of fusogenic endosomal vesicles.J Cell Biol,1993,120:1357-1369.
7Fatter CE,White lJ.Annexins anti endocytosis.Traffic,2007,8:951-958.
8Kirshner J,Schumann D,Shivcly JE.CEACAMI,a cell-cell adhesion molecule,directly associates with annexin Ⅱ in a three-dimensional model of mammary morphngenesis.J Biol Chem,2003,278:50338-50345.
9Gerke V,Moss SE.Annexins:from structure to function.Physiol Rev,2002,82:331-371.
10Hajjar KA,Jacovina AT,Chacko J.An endothelial cell receptor for plasminogen/tissue plasminogen activator.I.Identity with annexin Ⅱ.J Biol Chem,1994,269:21191-21197.
